Back

Stereotactic arrhythmia radioablation (STAR): safety and efficacy in first 50 patients

28 August 2026 (13:45 - 13:55)
Organised by: Logo
Congress Presentation Part of: Latest developments in ventricular arrhythmia management and outcomes Radiotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Calum Redpath

University of Ottawa Heart Institute, Ottawa (Canada)

5 More presentations in this session

Presentation thumbnail
Refining arrhythmic mitral valve prolapse definition by including left ventricular origin of arrhythmias: Insights from long-term cardiac monitoring
Doctor C. Bugge (Oslo, NO)
Abstract Slides Video
Presentation thumbnail
Unipolar local activation time outperforms bipolar electrograms for localizing outflow tract premature ventricular contractions
Miss L. Shu (Hangzhou, CN)
Abstract Slides Video
Presentation thumbnail
Cardiac magnetic resonance for assessment of pulsed field ablation-induced ventricular septal lesions: correlation with pathology and functional outcomes in a porcine model
Doctor Q. Chen (Shanghai, CN)
Abstract Slides Video
Presentation thumbnail
Heart transplantation in electrical storm and refractory ventricular arrhythmia patients
Doctor R. Rakza (Rennes, FR)
Abstract Slides Video
Presentation thumbnail
Benefits of stereotactic arrhythmia radioablation (STAR) for ventricular tachycardia at one year similar in ischemic and non-ischemic patients
Doctor C. Redpath (Ottawa, CA)
Abstract Slides Video

Access the full session

Session thumbnail
Latest developments in ventricular arrhythmia management and outcomes
Video

The Event

Event poster

ESC Congress 2026

28 August 2026 13:45 CET
You may be interested in
thumbnail
Congress Presentation
Ablation of ventricular tachycardia with radiotherapy: a new frontier
20 June 2026
thumbnail
Congress Session
Ventricle - Round 1 - SCD
16 April 2023
thumbnail
Congress Presentation
Radiosurgery for ventricular tachycardia (RAVENTA): Final results of a German multicenter multiplatform feasibility trial
31 March 2025
thumbnail
Congress Presentation
Stereotactic arrhythmia radiotherapy for refractory ventricular tachycardia: Interim safety and efficacy results from the ongoing prospective STARNL-2 trial
12 April 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources